Advertise on podcast: Reevaluating

Clinical trials to evaluate new drugs are typically built around one design, the randomized controlled trial, but this method has come under scrutiny in recent years for being expensive, lengthy, and cumbersome. In this podcast you'll hear from experts asking if alternative designs would be better for determining the safety and efficacy of new therapies. This podcast was produced following a conference on this topic held in partnership between the NYU School of Medicine and the Academy. It was made possible with support from Johnson and Johnson.

Clinical trials to evaluate new drugs are typically built around one design, the randomized controlled trial, but this method has come under scrutiny in recent years for being expensive, lengthy, and cumbersome. In this podcast you'll hear from experts asking if alternative designs would be better for determining the safety and efficacy of new therapies. This podcast was produced following a conference on this topic held in partnership between the NYU School of Medicine and the Academy. It was made possible with support from Johnson and Johnson.

Clinical trials to evaluate new drugs are typically built around one design, the randomized controlled trial, but this method has come under scrutiny in recent years for being expensive, lengthy, and cumbersome. In this podcast you'll hear from experts asking if alternative designs would be better for determining the safety and efficacy of new therapies. This podcast was produced following a conference on this topic held in partnership between the NYU School of Medicine and the Academy. It was made possible with support from Johnson and Johnson.

Clinical trials to evaluate new drugs are typically built around one design, the randomized controlled trial, but this method has come under scrutiny in recent years for being expensive, lengthy, and cumbersome. In this podcast you'll hear from experts asking if alternative designs would be better for determining the safety and efficacy of new therapies. This podcast was produced following a conference on this topic held in partnership between the NYU School of Medicine and the Academy. It was made possible with support from Johnson and Johnson.

Clinical trials to evaluate new drugs are typically built around one design, the randomized controlled trial, but this method has come under scrutiny in recent years for being expensive, lengthy, and cumbersome. In this podcast you'll hear from experts asking if alternative designs would be better for determining the safety and efficacy of new therapies. This podcast was produced following a conference on this topic held in partnership between the NYU School of Medicine and the Academy. It was made possible with support from Johnson and Johnson.

Clinical trials to evaluate new drugs are typically built around one design, the randomized controlled trial, but this method has come under scrutiny in recent years for being expensive, lengthy, and cumbersome. In this podcast you'll hear from experts asking if alternative designs would be better for determining the safety and efficacy of new therapies. This podcast was produced following a conference on this topic held in partnership between the NYU School of Medicine and the Academy. It was made possible with support from Johnson and Johnson.

Clinical trials to evaluate new drugs are typically built around one design, the randomized controlled trial, but this method has come under scrutiny in recent years for being expensive, lengthy, and cumbersome. In this podcast you'll hear from experts asking if alternative designs would be better for determining the safety and efficacy of new therapies. This podcast was produced following a conference on this topic held in partnership between the NYU School of Medicine and the Academy. It was made possible with support from Johnson and Johnson.

Clinical trials to evaluate new drugs are typically built around one design, the randomized controlled trial, but this method has come under scrutiny in recent years for being expensive, lengthy, and cumbersome. In this podcast you'll hear from experts asking if alternative designs would be better for determining the safety and efficacy of new therapies. This podcast was produced following a conference on this topic held in partnership between the NYU School of Medicine and the Academy. It was made possible with support from Johnson and Johnson.

Clinical trials to evaluate new drugs are typically built around one design, the randomized controlled trial, but this method has come under scrutiny in recent years for being expensive, lengthy, and cumbersome. In this podcast you'll hear from experts asking if alternative designs would be better for determining the safety and efficacy of new therapies. This podcast was produced following a conference on this topic held in partnership between the NYU School of Medicine and the Academy. It was made possible with support from Johnson and Johnson.

Clinical trials to evaluate new drugs are typically built around one design, the randomized controlled trial, but this method has come under scrutiny in recent years for being expensive, lengthy, and cumbersome. In this podcast you'll hear from experts asking if alternative designs would be better for determining the safety and efficacy of new therapies. This podcast was produced following a conference on this topic held in partnership between the NYU School of Medicine and the Academy. It was made possible with support from Johnson and Johnson.